GlassScriptPhysician profile
Gary W Bedel
NPI 1700803780
$15,757.64
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,513 · 2020: $2,229 · 2021: $2,532 · 2022: $1,240 · 2023: $125 · 2024: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $3,632.60 | 2019 | |
| Pfizer INC. | $1,963.76 | 2019-2024 | |
| Amgen INC. | $1,892.51 | 2019-2023 | Repatha |
| Novo Nordisk INC | $1,423.36 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $946.30 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $871.51 | 2019-2022 | |
| Glaxosmithkline, LLC. | $827.28 | 2019-2022 | |
| Lilly USA, LLC | $531.42 | 2019-2022 | |
| Abbvie INC. | $447.39 | 2019-2022 | |
| Amarin Pharma, INC. | $420.58 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $281.26 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $249.65 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $248.68 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $220.31 | 2021 | |
| Daiichi Sankyo INC. | $177.62 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.55 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.96 | 2019-2021 | |
| Esperion Therapeutics, INC. | $155.82 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $143.78 | 2019 | |
| Celgene Corporation | $125.05 | 2019 | |
| Allergan, INC. | $123.73 | 2019-2020 | |
| Romark Laboratories, Lc | $121.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $97.99 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $89.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $70.67 | 2021 | |
| Biogen, INC. | $54.16 | 2021-2022 | |
| Abbott Laboratories | $53.64 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $50.93 | 2021-2022 | |
| Antares Pharma, INC. | $42.37 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $41.62 | 2022 | |
| Astellas Pharma US INC | $38.28 | 2019-2021 | |
| Mylan Specialty L.P. | $17.57 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.39 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.54 | 2022 | |
| Eisai INC. | $16.10 | 2021 | |
| Nabriva Therapeutics, Plc | $12.04 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Bedel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.